PA-PMI
19.8.2020 17:02:05 CEST | Business Wire | Press release
Project Management Institute (PMI), the world's leading association for the project management profession, invites professionals across the globe to register for Virtual Experience Series titled, “The Community: Together We Rise ” on 25 August 2020 from 11 a.m. - 5 p.m. Eastern Daylight Time. The second event in this innovative series is headlined by comedian and host of The Daily Show ® program Trevor Noah, and hosted by journalist, talk show host, and executive producer, Tamron Hall. Additionally, more than 20 industry experts will lead thought-provoking sessions, including artificial intelligence thought leader and author of Girl Decoded: A Scientist’s Quest to Reclaim Our Humanity by Bringing Emotional Intelligence to Technology , Dr. Rana el Kaliouby.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005404/en/
The Virtual Experience Series connects participants with global innovators, inspirational voices, and project leaders to help them navigate a world defined by challenge, and embrace the opportunity to make a new reality. In the opening session, Trevor Noah will discuss how he taps into his inner project manager to galvanize a community, practice agility daily, and lead a global team. In 2015, Trevor succeeded long-time program host, Jon Stewart, and has received various accolades, including a Primetime Emmy Award win. In response to COVID-19, Trevor began hosting a modified virtual version of The Daily Show called The Daily Social Distancing Show with Trevor Noah to continue tackling the biggest stories in news, politics and pop culture. This year, The Daily Show received eight Emmy nominations.
Participants who want to boost their career or pivot to a new one can discover the Brand You Hub containing useful tips for all professionals looking to adapt and thrive in this new dynamic work environment. They can also network with project professionals in the Networking Hub and join a fireside chat with leaders of Fortune 500 organizations to explore the human side of leading during disruption, as well as lessons and takeaways from the pandemic.
“Now more than ever, PMI’s goal is to bring to the forefront insights and resources that are essential to help empower people to move projects forward and turn ideas into reality,” said Michael DePrisco, vice president, global experience & solutions at PMI. “In our post-COVID new work ecosystem, teams are putting increased emphasis on collaborative leadership and empathy to help deliver value in our virtual workplace. These are what we refer to as ‘power skills’ and PMI is here to provide the resources necessary to build and perfect these skillsets.”
Each month, the Virtual Experience Series will feature a new roster of thought-leading personalities and industry experts. Upcoming series dates and topics include:
- 9 September - A Deep Dive in Organizational Agility: Adaptability, Resilience and Learning
- 20 October - The World: Our Global Impact
- 12 November - A Deep Dive in Business Analysis: Drawing a Map to the Future
- 9 December - The Future: Forging Our Path Forward
Registration for PMI members is $99 for a single experience or $359 for the entire series. Registration for non-members is $149 for a single experience or $899 for the event series. Purchasing a series pass includes complimentary on-demand access to the PMI® Talent and Technology Symposium, which took place in June, and select recorded sessions for attendees to peruse through January 2021. Each session is eligible for professional development units (PDUs) toward maintaining PMI® certifications.
For more information on this event and to register, visit experience.pmi.org .
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com® website creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute .
“The Daily Show” is a registered mark of Comedy Partners.
“PMI” and “Projectmanagement.com” are registered marks of Project Management Institute, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200819005404/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom